AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,Study
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 131
- Registration Number
- NCT01254721
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis
Phase 2
Completed
- Conditions
- BronchiectasisLung DiseaseRespiratory Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 83
- Registration Number
- NCT01255592
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
A Drug-Drug Interaction Study Between AZD1981 and Pravastatin to Study the Effect of AZD1981 on the Kinetics of Pravastatin
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2011-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT01254461
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
- First Posted Date
- 2010-11-30
- Last Posted Date
- 2012-10-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 101
- Registration Number
- NCT01249651
- Locations
- 🇨🇳
Research Site, Bejing, China
Predictive Questionnaires for Risk of Acute COPD (Chronic Obstructive Pulmonary Disease) Exacerbations
Completed
- Conditions
- COPD
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 634
- Registration Number
- NCT01248507
- Locations
- 🇪🇸
Nycomed Pharma S.A., Madrid, Spain
Assessment of the Safety and Pharmacokinetics of Single and Multiple Oral Doses of AZD4316 in Healthy Subjects
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 128
- Registration Number
- NCT01247103
- Locations
- 🇬🇧
Research Site, London, United Kingdom
An Open-Label, Dose-Escalation Study of AZD2461
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT01247168
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
A Study of Fostamatinib in Subjects With Impaired Kidney Function
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2011-06-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT01245790
- Locations
- 🇺🇸
Research Site, Orlando, Florida, United States
Hypoglycemia- and Weight-related Quality of Life in Patients With Diabetes Mellitus Type 2 on Sulfonylurea Derivatives.
Terminated
- Conditions
- Diabetes Mellitus Type 2
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT01244646
- Locations
- 🇳🇱
Research Site, Zutphen, Netherlands
Polish Survey on the Efficacy of the Hypercholesterolemia Treatment
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2012-04-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1500
- Registration Number
- NCT01243255